Biotechnology

Allakos

Allakos released FY2025 Q1 earnings on May 7, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2912 (forecast USD -0.29)

Allakos Inc narrows its loss per share

Allakos Inc projects quarterly loss of 29 cents

Allakos released FY2024 Q4 earnings on March 12 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS 0.0042 USD (forecast -0.172 USD)

Allakos released FY2024 Annual Earnings on March 12 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.3043 USD (forecast -1.482 USD)

Allakos Stops Development of AK006 for Chronic Spontaneous Urticaria and Cuts Workforce by 75%

Allakos released FY2024 9 Months Earnings on November 6, 2024 (EST) with actual revenue of USD 0 and EPS of USD -1.3153

Allakos released FY2024 Q3 earnings on November 6 (EST), actual EPS -0.2063 (forecast -0.242)

Allakos Announces Positive Phase I Trial Results for Subcutaneous AK006

Allakos released its Semi-annual 2024 earnings on August 7, 2024 (EST), with revenue of 0 and EPS of -1.1073

Allakos announces positive results from Phase 1 trial of Ak006

Allakos announces first dosing of patients in Phase 1 trial of AK006 in chronic spontaneous urticaria

Allakos released FY2024 Q1 earnings on May 9, 2024 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -0.808 (forecast USD -0.4371)

Allakos reports quarterly loss below expectations

Allakos released its Q3 2023 earnings on November 13, 2023 (EST), with revenue of 0 and EPS of -1.423

Allakos released its Semi-annual 2023 earnings on August 9, 2023 (EST), with revenue of 0 and EPS of -0.8988

SMX Security Matters

Treasure Gbl

Wheeler Real Estate

Dreamland

Irobot

Praxis Precision Medicines

DigitalBridge

ChargePoint

AiRWA

BiomX

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap